Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
7230997 | Biosensors and Bioelectronics | 2016 | 7 Pages |
Abstract
Two novel sandwich-based immunoassays for prostate cancer (PCa) diagnosis are reported, in which the primary antibody for capture is replaced by a DNA aptamer. The assays, which can be performed in parallel, were developed in a microfluidic device and tested for the detection of free Prostate Specific Antigen (fPSA). A secondary antibody (Aptamer-Antibody Assay) or a lectin (Aptamer-Lectin Assay) is used to quantify, by chemiluminescence, both the amount of fPSA and its glycosylation levels. The use of aptamers enables a more reliable, selective and controlled sensing of the analyte. The dual approach provides sensitive detection of fPSA along with selective fPSA glycoprofiling, which is of significant importance in the diagnosis and prognosis of PCa, as tumor progression is associated with changes in fPSA glycosylation. With these approaches, we can potentially detect 0.5Â ng/mL of fPSA and 3Â ng/mL of glycosylated fPSA using Sambucus nigra (SNA) lectin, both within the relevant clinical range. The approach can be applied to a wide range of biomarkers, thus providing a good alternative to standard antibody-based immunoassays with significant impact in medical diagnosis and prognosis.
Related Topics
Physical Sciences and Engineering
Chemistry
Analytical Chemistry
Authors
Pawan Jolly, Pavel Damborsky, Narayanan Madaboosi, Ruben R.G. Soares, Virginia Chu, João P. Conde, Jaroslav Katrlik, Pedro Estrela,